VEGF Trap-Eye Submitted For EU Marketing Authorization For Treatment Of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced thatBayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion (CRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).